3rd May 2011

Mirada Medical Develops Radiation Therapy Workflows for Multidisciplinary Cancer Management, on Show at ESTRO Anniversary Conference, London

Bridging radiology and radiation oncology, innovative RT workflows developed by Mirada Medical Limited are the latest in Mirada’s portfolio of oncology products on display at the European Society for Therapeutic Radiology and Oncology (ESTRO) Anniversary Conference, London UK 8th-11th May 2011. New RT workflows in XD3, Mirada’s multi-modality and multi-timepoint oncology software, harness the power of CT-CT registration between the planning CT and PET/CT to provide functional imaging information for target delineation with accuracy and speed. XD3’s registration engine also performs tri-modal fusion between PET/CT and MRI in order to immediately realise the benefits of PET/MRI for treatment planning, without having a PET/MRI scanner. This software-based PET/MRI presents powerful information during tumour assessment, staging, and delineation, with better visualisation of soft tissue abnormalities and tumours best localised using MRI, such as lymph nodes in the neck. “Mirada's deformable registration software is fast and accurate across multiple modalities and allows us to fuse MRI, PET/CT and SPECT/CT with planning volumes. This unlocks the potential to incorporate all of the diagnostic imaging in our planning process.” Says Prof. Gillies McKenna, Director of the Gray Institute for Radiation Oncology and Biology at the University of Oxford. At ESTRO, Mirada will also be demonstrating new tools for closing the loop of patient management between diagnosis and therapy. Mirada’s Chief Scientist Dr. Timor Kadir says “In order to fully realise the benefits of functional imaging and multi-sequence MRI in therapy planning, clinical specialists need both tools and quality control measures to adjust targets based on treatment response during a course of radiation therapy. We have been working with our clinical partners to develop and hone such tools within XD3, while keeping the workflow simple and elegant.” Central to XD3 is the ability to assess, quantify and compare patient studies across unlimited timepoints, in custom display layouts, simultaneously. Through registration, users can easily propagate VOIs across timepoints, creating tables and graphs which track quantification statistics for comparison and reporting. Statistics are configurable for each user and include PERCIST, RECIST, WHO, among others. To further support and streamline clinical workflow, Mirada has created a product, Caseaccess, which is complimentary to XD3 and allows remote referrers to review a case once read and reported. Integral to the design of XD3 is operation in conjunction with any PACS system; native integrations are also available through selected partners including Carestream, Vital Images, Sectra and McKesson. The vendor neutral nature of Mirada’s products also means they can be used with all the major treatment planning companies for transfer of image data and contours. Mirada’s oncology product portfolio and newest technology developments will be demonstrated during the exhibition, booth 410, the European Society for Therapeutic Radiology and Oncology (ESTRO) Anniversary Conference, London UK 8th – 11th May 2011.